V-Wave

V-Wave is a privately held company headquartered in Israel, with a focus on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). The company, founded in 2010, aims to address the significant impact of HF, which affects millions of people worldwide by providing solutions for patients who continue to experience disabling symptoms or require hospitalization even with optimized medical treatment. V-Wave's flagship product is a proprietary interatrial shunt designed to alleviate symptoms, decrease hospitalization rates, improve exercise capacity, and enhance overall quality of life for patients. The company's efforts stem from a talented team of engineers and medical scientists in Israel. Their senior management brings decades of experience in successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices. In December 2021, V-Wave secured a significant $98.00M Series C investment from a diverse group of investors, including BRM Group, Pontifax, Pura Vida Investments, TriVentures, Aperture Venture Partners, Deerfield Management, Endeavour Vision, GHS Fund, Israeli Secondary Fund, Johnson & Johnson Innovation – JJDC, signifying the confidence of industry leaders in the company's mission and potential impact. V-Wave's commitment to addressing a critical unmet medical need in the healthcare and biotechnology sectors positions it as a promising venture for potential investors.